Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of Sandra J. Horning, M.D., to senior vice president, global head, Clinical Development Hematology/Oncology.
The US Food and Drug Administration announced that it is working with the maker of Xigris (drotrecogin alfa activated), Eli Lilly and Company, to further evaluate the incidence of serious bleeding events and death in patients who receive Xigris, a drug used to treat severe sepsis (a blood stream infection).
Data from a study published in JAMA concluded that evidence "does not support the notion that brand-name drugs used in cardiovascular disease are superior to generic drugs," despite numerous editorials that "counsel against the interchangeability of generic drugs," according to the study authors.
AstraZeneca's Crestor (rosuvastatin) significantly reduced the risk of cardiovascular events and related deaths by 44 percent, compared to placebo, in people with normal cholesterol levels who had elevated levels of C-reactive protein (CRP), according to results from the JUPITER study presented at the American Heart Association Scientific Sessions.
Sr. S V VeeramaniPresidente y Director GerenteFourrts (India) Laboratories Pvt Ltd (Chennai)PERFILFundador y Presidente de Fourrts (India) Laboratorios Pvt Limited, una compañía farmacéutica creciendo rápidamente, basada en Chennai, el Sr. Veeramani tiene más de 30 años de la experiencia exitosa en la industria farmacéutica. Fourrts ha ganado el Premio de la Excelencia de la Calidad